Cargando…
Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635029/ https://www.ncbi.nlm.nih.gov/pubmed/34867403 http://dx.doi.org/10.3389/fphar.2021.773204 |
_version_ | 1784608221998088192 |
---|---|
author | Wang, Xin Gou, Xiaoli Yu, Xiaojuan Bai, Dongdong Tan, Bowei Cao, Pingfeng Qian, Meilin Zheng, Xiaoxiao Wang, Hairong Tang, Pingming Zhang, Chen Ye, Fei Ni, Jia |
author_facet | Wang, Xin Gou, Xiaoli Yu, Xiaojuan Bai, Dongdong Tan, Bowei Cao, Pingfeng Qian, Meilin Zheng, Xiaoxiao Wang, Hairong Tang, Pingming Zhang, Chen Ye, Fei Ni, Jia |
author_sort | Wang, Xin |
collection | PubMed |
description | Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously impede their development. Peripherally-restricted KOR agonists have a poor ability to penetrate into the CNS system, so that CNS-related adverse effects can be ameliorated or even abolished. However, the only approved peripherally-restricted KOR agonist CR845 remains some frequent CNS adverse events. In the present study, we aim to address pharmacological profiles of HSK21542, with an expectation to provide a safe and effective alternative for patients who are suffering from pain and pruritus. The in vitro experimental results showed that HSK21542 was a selective and potent KOR agonist with higher potency than CR845, and had a brain/plasma concentration ratio of 0.001, indicating its peripheral selectivity. In animal models of pain, HSK21542 significantly inhibited acetic acid-, hindpaw incision- or chronic constriction injury-induced pain-related behaviors, and the efficacy was comparable to CR845 at 15 min post-dosing. HSK21542 had a long-lasting analgesic potency with a median effective dose of 1.48 mg/kg at 24 h post-drug in writhing test. Meanwhile, the antinociceptive activity of HSK21542 was effectively reversed by a KOR antagonist nor-binaltorphimine. In addition, HSK21542 had powerful antipruritic activities in compound 48/80-induced itch model. On the other hand, HSK21542 had a weak ability to produce central antinociceptive effects in a hot-plate test and fewer effects on the locomotor activity of mice. HSK21542 didn’t affect the respiratory rate of mice. Therefore, HSK21542 might be a safe and effective KOR agonist and promising candidate for treating pain and pruritus. |
format | Online Article Text |
id | pubmed-8635029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86350292021-12-02 Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch Wang, Xin Gou, Xiaoli Yu, Xiaojuan Bai, Dongdong Tan, Bowei Cao, Pingfeng Qian, Meilin Zheng, Xiaoxiao Wang, Hairong Tang, Pingming Zhang, Chen Ye, Fei Ni, Jia Front Pharmacol Pharmacology Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously impede their development. Peripherally-restricted KOR agonists have a poor ability to penetrate into the CNS system, so that CNS-related adverse effects can be ameliorated or even abolished. However, the only approved peripherally-restricted KOR agonist CR845 remains some frequent CNS adverse events. In the present study, we aim to address pharmacological profiles of HSK21542, with an expectation to provide a safe and effective alternative for patients who are suffering from pain and pruritus. The in vitro experimental results showed that HSK21542 was a selective and potent KOR agonist with higher potency than CR845, and had a brain/plasma concentration ratio of 0.001, indicating its peripheral selectivity. In animal models of pain, HSK21542 significantly inhibited acetic acid-, hindpaw incision- or chronic constriction injury-induced pain-related behaviors, and the efficacy was comparable to CR845 at 15 min post-dosing. HSK21542 had a long-lasting analgesic potency with a median effective dose of 1.48 mg/kg at 24 h post-drug in writhing test. Meanwhile, the antinociceptive activity of HSK21542 was effectively reversed by a KOR antagonist nor-binaltorphimine. In addition, HSK21542 had powerful antipruritic activities in compound 48/80-induced itch model. On the other hand, HSK21542 had a weak ability to produce central antinociceptive effects in a hot-plate test and fewer effects on the locomotor activity of mice. HSK21542 didn’t affect the respiratory rate of mice. Therefore, HSK21542 might be a safe and effective KOR agonist and promising candidate for treating pain and pruritus. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8635029/ /pubmed/34867403 http://dx.doi.org/10.3389/fphar.2021.773204 Text en Copyright © 2021 Wang, Gou, Yu, Bai, Tan, Cao, Qian, Zheng, Wang, Tang, Zhang, Ye and Ni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Xin Gou, Xiaoli Yu, Xiaojuan Bai, Dongdong Tan, Bowei Cao, Pingfeng Qian, Meilin Zheng, Xiaoxiao Wang, Hairong Tang, Pingming Zhang, Chen Ye, Fei Ni, Jia Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title | Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title_full | Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title_fullStr | Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title_full_unstemmed | Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title_short | Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch |
title_sort | antinociceptive and antipruritic effects of hsk21542, a peripherally-restricted kappa opioid receptor agonist, in animal models of pain and itch |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635029/ https://www.ncbi.nlm.nih.gov/pubmed/34867403 http://dx.doi.org/10.3389/fphar.2021.773204 |
work_keys_str_mv | AT wangxin antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT gouxiaoli antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT yuxiaojuan antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT baidongdong antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT tanbowei antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT caopingfeng antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT qianmeilin antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT zhengxiaoxiao antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT wanghairong antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT tangpingming antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT zhangchen antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT yefei antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch AT nijia antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch |